Dose-ranging trial of OPC-249 powder inhalation in patients with pain due to osteoporosis
Phase 2
- Conditions
- Pain due to osteoporosis
- Registration Number
- JPRN-jRCT2080220414
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Patients who fulfill all of the following items
-Patients with primary osteoporosis
-Patients who have existing 1-4 vertebral fractures
-Patients with back pain persisting for one week or more
-Postmenopausal women between 46 and less than 80 years of age
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy, safety
- Secondary Outcome Measures
Name Time Method